A5083364333- Multiple Myeloma Research and Treatments
- Complement system in diseases
- Renal Diseases and Glomerulopathies
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Hemoglobinopathies and Related Disorders
- Multiple and Secondary Primary Cancers
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Adenosine and Purinergic Signaling
- Platelet Disorders and Treatments
- Blood groups and transfusion
- Heparin-Induced Thrombocytopenia and Thrombosis
- Peptidase Inhibition and Analysis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Viral-associated cancers and disorders
- T-cell and Retrovirus Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Lysosomal Storage Disorders Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- COVID-19 Impact on Reproduction
- Meningioma and schwannoma management
- Statistical Methods in Clinical Trials
- Lung Cancer Research Studies
Cleveland Clinic Florida
2006-2024
Cleveland Clinic
2010
National Institutes of Health
2002
We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Paroxysmal nocturnal hemoglobinuria (PNH) is a debilitating and life-threatening disease in which lysis of PNH red blood cells frequently manifests with chronic hemolysis, anemia, thrombosis. Renal damage associated hemosiderosis and/or microvascular We determined the incidence renal dysfunction or damage, defined by stages kidney (CKD), large cohort patients evaluated safety efficacy complement inhibitor eculizumab altering its progression. was observed 65% study population at baseline 21%...
Abstract Background Cardio-Oncology (CO) is a new subspecialty that thrives mostly in large academic quaternary centers. This study describes how to establish successful cardio-oncology program, with limited resources, order effectively manage the unique care required by this patient population. Methods Clinical data was collected from 25 consecutive months. There were four foundational elements CO program: 1. integrating staff and resources Heart Vascular, Cancer Centers; 2. Education...
BackgroundDisparities in access to triplet and quadruplet therapy for multiple myeloma (MM) patients remain a challenge the United States. We aimed investigate demographic socioeconomic factors influencing treatment using NCDB data.Patients MethodsWe analyzed 101,867 MM diagnosed between 2004 2020. Multinomial logistic regression multivariable cox were employed assess survival, respectively.ResultsBlack exhibited significantly lower odds of receiving compared White patients. Socioeconomic...
7563 Background: Palliative care (PC) can improve the quality of life for patients with multiple myeloma (MM). Despite its recognized importance, research gaps persist in understanding factors influencing PC accessibility and utilization, particularly diverse MM patient landscape real-world setting. This study explores potential associations between race, ethnicity, socioeconomic factors, access USA. Methods: Utilizing NCDB, we identified 202,949 diagnosed from 2004 to 2020. Multivariate...
Composite lymphoma is defined as two or more lymphomas with distinct morphological and immunophenotypical characteristics synchronously diagnosed at the same anatomical site. rare, most common combination follicular (FL) associated diffuse large B cell lymphoma, followed by FL classic Hodgkin’s (HL). Histologically, composite display a mixed pattern zonal distribution of each component. poses diagnostic challenge, especially when components are in lymph node. Here, we report case HL 11 years...
Waldenstrom's macroglobulinemia (WM) is an indolent B-cell non-Hodgkin lymphoma characterized by lymphoplasmacytic histology in the bone marrow with monoclonal IgM. Median survival can be excess of 10 years. The 5-year cumulative incidence death low at about 10%. One-third all-cause specific mortality due to for which histologic transformation (HT) rare. Here we present a case 60-year-old man longstanding untreated WM, presenting minimally symptomatic diffuse large (DLBCL), accompanying...
Abstract Background: Multi-agent therapy consisting of Immunomodulatory Drug (Lenalidomide), Proteasome Inhibitor (Bortezomib), and Dexamethasone revolutionized patient outcomes in Multiple Myeloma (MM). In this retrospective analysis, the NCDB database was used to evaluate determinants that affected access multi-agent among MM patients who were treated commission on cancer-accredited facilities across USA. Methods: Using NCDB, we identified N= 171,261 diagnosed with from 2004 2017....
e20035 Background: The survival of older adults with multiple myeloma (MM) continues to improve due advancements in therapy but there is limited real-world data around the outcome elderly (≥ 75 years old) MM patients. These patients are at risk comorbidities, frailty and potential for reduced tolerance treatment. In this IRB approved retrospective analysis, NCDB was used evaluate 30-day mortality determinants overall (OS) who were treated commission on cancer (CoC) accredited facilities...
e20060 Background: Due to its rarity, comprehensive studies on plasmacytoma are limited. There two main subtypes: solitary bone (P-Bone) and extramedullary (P-EM). In this IRB approved retrospective analysis, the NCDB was used evaluate clinical features factors affecting overall survival of patients with who were treated at commission cancer (CoC) accredited facilities across USA. Methods: Using NCDB, we identified N = 6,579 from 2004 2017, after excluding multiple myeloma patients. 4,816...